Context:
Financial Statements:
| Column 1                                                                                                | Column 2   | Column 3      | Column 4   | Column 5          | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   |
|:--------------------------------------------------------------------------------------------------------|:-----------|:--------------|:-----------|:------------------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                                                                         |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
|                                                                                                         |            | June 28, 2020 |            | December 29, 2019 |            |            |            |            |             |             |             |             |             |             |
| ASSETS                                                                                                  |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Current assets:                                                                                         |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Cash and cash equivalents                                                                               |            | $             | 11,174     |                   |            | 17,305     |            |            |             |             |             |             |             |             |
| Marketable securities                                                                                   |            | 7,961         |            |                   | 1,982      |            |            |            |             |             |             |             |             |             |
| Accounts receivable, trade, less allowances for doubtful accounts and credit losses $334 (2019, $226)   |            | 14,645        |            |                   | 14,481     |            |            |            |             |             |             |             |             |             |
| Inventories (Note 2)                                                                                    |            | 9,424         |            |                   | 9,020      |            |            |            |             |             |             |             |             |             |
| Prepaid expenses and other                                                                              |            | 2,588         |            |                   | 2,392      |            |            |            |             |             |             |             |             |             |
| Assets held for sale (Note 10)                                                                          |            | 100           |            |                   | 94         |            |            |            |             |             |             |             |             |             |
| Total current assets                                                                                    |            | 45,892        |            |                   | 45,274     |            |            |            |             |             |             |             |             |             |
| Property, plant and equipment at cost                                                                   |            | 44,056        |            |                   | 43,332     |            |            |            |             |             |             |             |             |             |
| Less: accumulated depreciation                                                                          |            | (26,458)      |            |                   | (25,674)   |            |            |            |             |             |             |             |             |             |
| Property, plant and equipment, net                                                                      |            | 17,598        |            |                   | 17,658     |            |            |            |             |             |             |             |             |             |
| Intangible assets, net (Note 3)                                                                         |            | 47,413        |            |                   | 47,643     |            |            |            |             |             |             |             |             |             |
| Goodwill (Note 3)                                                                                       |            | 33,890        |            |                   | 33,639     |            |            |            |             |             |             |             |             |             |
| Deferred taxes on income (Note 5)                                                                       |            | 7,805         |            |                   | 7,819      |            |            |            |             |             |             |             |             |             |
| Other assets                                                                                            |            | 5,782         |            |                   | 5,695      |            |            |            |             |             |             |             |             |             |
| Total assets                                                                                            |            | $             | 158,380    |                   |            | 157,728    |            |            |             |             |             |             |             |             |
| LIABILITIES AND SHAREHOLDERS’ EQUITY                                                                    |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Current liabilities:                                                                                    |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Loans and notes payable                                                                                 |            | $             | 5,332      |                   |            | 1,202      |            |            |             |             |             |             |             |             |
| Accounts payable                                                                                        |            | 6,765         |            |                   | 8,544      |            |            |            |             |             |             |             |             |             |
| Accrued liabilities                                                                                     |            | 8,940         |            |                   | 9,715      |            |            |            |             |             |             |             |             |             |
| Accrued rebates, returns and promotions                                                                 |            | 11,790        |            |                   | 10,883     |            |            |            |             |             |             |             |             |             |
| Accrued compensation and employee related obligations                                                   |            | 2,313         |            |                   | 3,354      |            |            |            |             |             |             |             |             |             |
| Accrued taxes on income (Note 5)                                                                        |            | 1,632         |            |                   | 2,266      |            |            |            |             |             |             |             |             |             |
| Total current liabilities                                                                               |            | 36,772        |            |                   | 35,964     |            |            |            |             |             |             |             |             |             |
| Long-term debt (Note 4)                                                                                 |            | 25,062        |            |                   | 26,494     |            |            |            |             |             |             |             |             |             |
| Deferred taxes on income(Note 5)                                                                        |            | 5,532         |            |                   | 5,958      |            |            |            |             |             |             |             |             |             |
| Employee related obligations (Note 6)                                                                   |            | 10,411        |            |                   | 10,663     |            |            |            |             |             |             |             |             |             |
| Long-term taxes payable (Note 5)                                                                        |            | 6,591         |            |                   | 7,444      |            |            |            |             |             |             |             |             |             |
| Other liabilities                                                                                       |            | 11,034        |            |                   | 11,734     |            |            |            |             |             |             |             |             |             |
| Total liabilities                                                                                       |            | 95,402        |            |                   | 98,257     |            |            |            |             |             |             |             |             |             |
| Commitments and Contingencies (Note 11)                                                                 |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Shareholders’ equity:                                                                                   |            |               |            |                   |            |            |            |            |             |             |             |             |             |             |
| Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) |            | $             | 3,120      |                   |            | 3,120      |            |            |             |             |             |             |             |             |
| Accumulated other comprehensive income (loss) (Note 7)                                                  |            | (15,533)      |            |                   | (15,891)   |            |            |            |             |             |             |             |             |             |
| Retained earnings                                                                                       |            | 113,898       |            |                   | 110,659    |            |            |            |             |             |             |             |             |             |
| Less: common stock held in treasury, at cost (487,466,000 and 487,336,000 shares)                       |            | 38,507        |            |                   | 38,417     |            |            |            |             |             |             |             |             |             |
| Total shareholders’ equity                                                                              |            | 62,978        |            |                   | 59,471     |            |            |            |             |             |             |             |             |             |
| Total liabilities and shareholders' equity                                                              |            | $             | 158,380    |                   |            | 157,728    |            |            |             |             |             |             |             |             |

---

| Column 1                                                                                  | Column 2   | Column 3                | Column 4   | Column 5     | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   |
|:------------------------------------------------------------------------------------------|:-----------|:------------------------|:-----------|:-------------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            | Fiscal Six Months Ended |            |              |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            | June 28,2020            |            | June 30,2019 |            |            |            |            |             |             |             |             |             |             |
| CASH FLOWS FROM OPERATING ACTIVITIES                                                      |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
| Net earnings                                                                              |            | $                       | 9,422      |              |            | 9,356      |            |            |             |             |             |             |             |             |
| Adjustments to reconcile net earnings to cash flows from operating activities:            |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
| Depreciation and amortization of property and intangibles                                 |            | 3,473                   |            |              | 3,466      |            |            |            |             |             |             |             |             |             |
| Stock based compensation                                                                  |            | 589                     |            |              | 572        |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
| Asset write-downs                                                                         |            | 33                      |            |              | 989        |            |            |            |             |             |             |             |             |             |
| Contingent consideration reversal                                                         |            | (983)                   |            |              | —          |            |            |            |             |             |             |             |             |             |
| Net gain on sale of assets/businesses                                                     |            | (60)                    |            |              | (2,079)    |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
| Deferred tax provision                                                                    |            | (428)                   |            |              | (694)      |            |            |            |             |             |             |             |             |             |
| Credit losses and accounts receivable allowances                                          |            | 117                     |            |              | 1          |            |            |            |             |             |             |             |             |             |
| Changes in assets and liabilities, net of effects from acquisitions and divestitures:     |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
| Increase in accounts receivable                                                           |            | (520)                   |            |              | (336)      |            |            |            |             |             |             |             |             |             |
| Increase in inventories                                                                   |            | (637)                   |            |              | (423)      |            |            |            |             |             |             |             |             |             |
| Decrease in accounts payable and accrued liabilities                                      |            | (2,319)                 |            |              | (444)      |            |            |            |             |             |             |             |             |             |
| Increase in other current and non-current assets                                          |            | (1,048)                 |            |              | (862)      |            |            |            |             |             |             |             |             |             |
| Decrease in other current and non-current liabilities                                     |            | (829)                   |            |              | (55)       |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
| NET CASH FLOWS FROM OPERATING ACTIVITIES                                                  |            | 6,810                   |            |              | 9,491      |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
| CASH FLOWS FROM INVESTING ACTIVITIES                                                      |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
| Additions to property, plant and equipment                                                |            | (1,287)                 |            |              | (1,493)    |            |            |            |             |             |             |             |             |             |
| Proceeds from the disposal of assets/businesses, net                                      |            | 87                      |            |              | 3,018      |            |            |            |             |             |             |             |             |             |
| Acquisitions, net of cash acquired                                                        |            | (949)                   |            |              | (5,346)    |            |            |            |             |             |             |             |             |             |
| Purchases of investments                                                                  |            | (8,551)                 |            |              | (1,517)    |            |            |            |             |             |             |             |             |             |
| Sales of investments                                                                      |            | 2,417                   |            |              | 2,132      |            |            |            |             |             |             |             |             |             |
| Proceeds from credit support agreements, net                                              |            | 672                     |            |              | —          |            |            |            |             |             |             |             |             |             |
| Other (primarily licenses and milestones)                                                 |            | (492)                   |            |              | 1          |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
| NET CASH USED BY INVESTING ACTIVITIES                                                     |            | (8,103)                 |            |              | (3,205)    |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
| CASH FLOWS FROM FINANCING ACTIVITIES                                                      |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
| Dividends to shareholders                                                                 |            | (5,164)                 |            |              | (4,918)    |            |            |            |             |             |             |             |             |             |
| Repurchase of common stock                                                                |            | (2,417)                 |            |              | (4,692)    |            |            |            |             |             |             |             |             |             |
| Proceeds from short-term debt                                                             |            | 2,717                   |            |              | 15         |            |            |            |             |             |             |             |             |             |
| Repayment of short-term debt                                                              |            | (17)                    |            |              | (12)       |            |            |            |             |             |             |             |             |             |
| Proceeds from long-term debt, net of issuance costs                                       |            | 1                       |            |              | 1          |            |            |            |             |             |             |             |             |             |
| Repayment of long-term debt                                                               |            | (11)                    |            |              | (1,005)    |            |            |            |             |             |             |             |             |             |
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net |            | 708                     |            |              | 463        |            |            |            |             |             |             |             |             |             |
| Other                                                                                     |            | (489)                   |            |              | 98         |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
| NET CASH USED BY FINANCING ACTIVITIES                                                     |            | (4,672)                 |            |              | (10,050)   |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
| Effect of exchange rate changes on cash and cash equivalents                              |            | (166)                   |            |              | 33         |            |            |            |             |             |             |             |             |             |
| Decrease in cash and cash equivalents                                                     |            | (6,131)                 |            |              | (3,731)    |            |            |            |             |             |             |             |             |             |
| Cash and Cash equivalents, beginning of period                                            |            | 17,305                  |            |              | 18,107     |            |            |            |             |             |             |             |             |             |
| CASH AND CASH EQUIVALENTS, END OF PERIOD                                                  |            | $                       | 11,174     |              |            | 14,376     |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
| Acquisitions                                                                              |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
| Fair value of assets acquired                                                             |            | $                       | 1,173      |              |            | 6,744      |            |            |             |             |             |             |             |             |
| Fair value of liabilities assumed and noncontrolling interests                            |            | (224)                   |            |              | (1,398)    |            |            |            |             |             |             |             |             |             |
| Net cash paid for acquisitions                                                            |            | $                       | 949        |              |            | 5,346      |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                         |            |              |            |            |            |            |             |             |             |             |             |             |

---

| Column 1                                       | Column 2   | Column 3                    | Column 4   | Column 5        | Column 6   | Column 7     | Column 8   | Column 9        | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   | Column 16   | Column 17   | Column 18   | Column 19   | Column 20   | Column 21   | Column 22   | Column 23   | Column 24   | Column 25   | Column 26   | Column 27   |
|:-----------------------------------------------|:-----------|:----------------------------|:-----------|:----------------|:-----------|:-------------|:-----------|:----------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                |            |                             |            |                 |            |              |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            | Fiscal Second Quarter Ended |            |                 |            |              |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            | June 28,2020                |            | Percentto Sales |            | June 30,2019 |            | Percentto Sales |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Sales to customers (Note 9)                    |            | $                           | 18,336     |                 |            | 100.0        | %          |                 | $           | 20,562      |             |             | 100.0       | %           |             |             |             |             |             |             |             |             |             |             |             |             |
| Cost of products sold                          |            | 6,579                       |            |                 | 35.9       |              |            | 6,940           |             |             | 33.8        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Gross profit                                   |            | 11,757                      |            |                 | 64.1       |              |            | 13,622          |             |             | 66.2        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Selling, marketing and administrative expenses |            | 4,993                       |            |                 | 27.2       |              |            | 5,546           |             |             | 27.0        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Research and development expense               |            | 2,707                       |            |                 | 14.8       |              |            | 2,666           |             |             | 13.0        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| In-process research and development            |            | 6                           |            |                 | 0.0        |              |            | —               |             |             | —           |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Interest income                                |            | (19)                        |            |                 | (0.1)      |              |            | (88)            |             |             | (0.4)       |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Interest expense, net of portion capitalized   |            | 45                          |            |                 | 0.3        |              |            | 83              |             |             | 0.4         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Other (income) expense, net                    |            | 24                          |            |                 | 0.1        |              |            | (1,683)         |             |             | (8.2)       |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Restructuring (Note 12)                        |            | 61                          |            |                 | 0.3        |              |            | 57              |             |             | 0.2         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Earnings before provision for taxes on income  |            | 3,940                       |            |                 | 21.5       |              |            | 7,041           |             |             | 34.2        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Provision for taxes on income (Note 5)         |            | 314                         |            |                 | 1.7        |              |            | 1,434           |             |             | 6.9         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| NET EARNINGS                                   |            | $                           | 3,626      |                 |            | 19.8         | %          |                 | $           | 5,607       |             |             | 27.3        | %           |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            |                             |            |                 |            |              |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| NET EARNINGS PER SHARE (Note 8)                |            |                             |            |                 |            |              |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Basic                                          |            | $                           | 1.38       |                 |            |              |            | $               | 2.11        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Diluted                                        |            | $                           | 1.36       |                 |            |              |            | $               | 2.08        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            |                             |            |                 |            |              |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| AVG. SHARES OUTSTANDING                        |            |                             |            |                 |            |              |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Basic                                          |            | 2,632.9                     |            |                 |            |              | 2,652.5    |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Diluted                                        |            | 2,665.5                     |            |                 |            |              | 2,691.7    |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |

---

English News:
Ethicon*, part of the Johnson & Johnson Medical Devices Company**, announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for transbronchial microwave ablation technology using robotic-assisted bronchoscopy, which is currently under development. The Breakthrough Devices Program is a voluntary program for certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The goal of the Breakthrough Devices Program is to provide patients and health care providers with timely access to these medical devices by speeding up their development, assessment, and review, while preserving the statutory standards for premarket approval, 510(k) clearance, and De Novo marketing authorization, consistent with the Agency's mission to protect and promote public health. \"Our acquisitions of NeuWave Medical and Auris Health have enabled us to bring two best-in-class platforms together as we work to develop this breakthrough technology,\" said Vladimir Makatsaria, Company Group Chairman of Ethicon, Johnson & Johnson. \"We look forward to working collaboratively with the FDA to help prioritize development and access for patients.\" Ethicon is a global leader in soft tissue microwave ablation and in flexible endoluminal robotics. The NEUWAVE Microwave Ablation System provides a minimally invasive option for soft tissue lesions, with more than 45,000 procedures performed to date. The MONARCH Platform provides improved reach into the periphery of the lung with continuous real-time vision, precision and control. MONARCH was the first robotic-assisted bronchoscopy system introduced in the United States with more than 3,300 procedures performed to date. \"Through our commitment to transform patients' lives, Johnson & Johnson is advancing innovative solutions with a focus on the prevention, interception and cure of some of the world's most complex, life-threatening diseases,\" saidAvrumSpira, M.D., M.Sc., Global Head of the Lung Cancer Initiative at Johnson & Johnson.*** \"This promising convergence oftechnologies offers an exciting opportunity to catalyze new approaches and solutions toimprove patient outcomes, andwelook forward to evaluating this device ina comprehensive clinicaldevelopment program.\" About EthiconEthicon, part of Johnson & Johnson Medical Devices Companies, has made significant contributions to surgery for more than 100 years from creating the first sutures, to revolutionizing surgery with minimally invasive procedures. Our continuing dedication to Shape the Future of Surgery is built on our commitment to help address the world's most pressing health care issues and improve and save more lives. Through Ethicon's surgical technologies and solutions including sutures, staplers, energy devices, trocars and hemostats and our commitment to treat serious medical conditions like obesity worldwide, we deliver innovation to make a life-changing impact. For more information, visitwww.ethicon.com. About Johnson & Johnson Medical Devices CompaniesAt Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people's healthcare experiences. In surgery, orthopaedics, vision and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere. *Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates. All other trademarks are the property of their respective owners. **The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopedics, vision and interventional solutions businesses within Johnson & Johnson's Medical Devices segment.*** The legal entity of the Lung Cancer Initiative at Johnson & Johnson is Johnson & Johnson Enterprise Innovation, Inc. Notice to Investors Concerning Forward-Looking Statements This press release contains \"forward-looking statements\" as defined in the Private Securities Litigation Reform Act of 1995 regarding NeuWave. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned \"Cautionary Note Regarding Forward-Looking Statements\" and \"Item 1A. Risk Factors,\" and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. SOURCE Ethicon, Inc.

Chinese News:
强生日前发布的2020年半年财务报告显示：今年上半年其全球营收为390.27亿美元，同比下降3.8%，其中医疗器械业务营收102.2亿美元，同比下降21.1%。有强生高管表示，新冠肺炎疫情发生后，大家减少外出所以受伤几率变小，创伤性手术也因此大幅减少。半年报显示，强生医疗器械板块四大业务均下滑，其中介入解决方案业务营收13.17亿美元，同比下降11.2%；骨科业务营收34.89亿美元，同比下降21.2%；外科手术业务营收36.51亿美元，同比下降23.1%；视力保健业务营收17.62亿美元，同比下降23%。

Japanese News:
米ジョンソン・エンド・ジョンソン（J&J）と同業のアボット・ラボラトリーズは、新型コロナウイルス感染拡大が続く中でも、医療機器分野の最も厳しい時期は既に過ぎつつあるとの認識を示した。 両社が発表した4～6月期（第2四半期）の業績は、慎重だった市場の事前予測を上回った。J&Jは今年の通期調整後利益予想を引き上げ、一方のアボットは、3カ月前に一旦取り下げていた通期の業績見通しを改めて示した。感染拡大初期には医療機関で緊急性の低い手術の延期や中止が相次ぎ、医療機器の販売が大きく落ち込んだが、現在はこうした状況が徐々に改善してきているという。 エドワード・ジョーンズ証券のアナリストであるアシュティン・エバンス氏は、「新型コロナの影響は4～6月期にピークを迎えた可能性が高い」と指摘した。 特にアボットは、新型コロナの検査キットや関連製品をいち早く市場投入したことで業績が伸び、4～6月期には検査関連だけで6億1500万ドル（約660億円）の売上を記録した。全体の純売上高は73億3000万ドル、調整後1株当たり利益は継続事業ベースで57セントとなり、それぞれ市場予想を上回った。また、通年の調整後1株利益については、少なくとも3.25ドルに達するとの見通しを示した。同社幹部は、米政権と連携しながら、サプライチェーンを強化し、医薬品供給への関税の影響を最小限に抑えるべきだと強調した。 一方、J&Jは2025年通期の売上高予想を従来の909億～917億ドルから916億～924億ドルへと、約7億ドル引き上げた。この背景には、新たに統合失調症や双極性うつ病の治療薬「カプリタ」の販売開始や、抗うつ薬「スプラバト」の年間売上が2028年までに30億～35億ドルに達する見通しなどが影響している。 また、通期の調整後1株利益予想を10.50～10.70ドルと設定。これは市場予想平均の10.43ドル（LSEGのデータに基づく）を大きく上回る数値だ。 第1四半期の業績を見ると、売上高は前年同期比2.4％増の218億9000万ドルとなり、調整後の1株利益も2.77ドルを記録。いずれもアナリストの予想（売上高215億6000万ドル、1株利益2.59ドル）を超えた。 J&Jの医薬品部門は売上高が市場予想を超え堅調だったものの、医療機器部門の売上高は前年同期比で増加したにもかかわらず、市場予測に届かなかった。

Spanish News:
El grupo estadounidense de productos farmacéuticos Johnson & Johnson ganó US$9.422 millones durante el primer semestre de 2020, en plena pandemia por el covid-19, un 0,7 % más que en el mismo periodo del año anterior. La compañía informó que entre enero y junio, el conglomerado especializado en la venta de productos de belleza y farmacéuticos facturó US$39.027 millones, un 3,8% menos que en el mismo intervalo del año pasado. Entre abril y junio, Johnson & Johnson ganó US$3.626 millones, 35% menos que en el mismo periodo de 2019; mientras que las ventas cayeron 10,8% interanual, hasta US$18.336 millones. Los analistas achacan la bajada del beneficio netos en el último trimestre a los efectos colaterales del covid-19, que ha obligado a muchos hospitales a posponer cirugías y tratamientos, lo que ha afectado gravemente a sus líneas de negocio. J&J ha revelado hoy que están intentando llegar a un acuerdo con los Institutos Nacionales de Salud para que les permita adelantar la última fase del ensayo de la vacuna, que tenían planeado llevar a cabo en septiembre. Asimismo, la compañía dijo que espera comenzar pruebas preliminares con 1.000 personas la próxima semana. Por sectores de negocio, el principal siguen siendo los productos farmacéuticos, que aumentaron un 2,1 % sus ventas, hasta los US$10.752 millones. La unidad de consumidores de la compañía, que fabrica por ejemplo productos de higiene bucal, generó US$3.296 millones en ingresos, 7% menos que el año previo. En general, la disminución en las ventas de dispositivos médicos fue parcialmente compensada por mayores ventas de otros productos de venta libre como el Tylenol o Listerine. En una jornada que se prevé bajista, los datos no despertaron gran interés en los inversores y, diez minutos antes del arranque de la sesión bursátil, los títulos de Johnson & Johnson avanzaban 0,2% en Wall Street. En lo que va de año, la farmacéutica se ha revalorizado 1,64%.

Greek News:
Η Johnson & Johnson ανακοίνωσε την εξαγορά της Momenta Pharmaceuticals έναντι 6,5 δισεκατομμυρίων δολαρίων, μέσω προσφοράς εξαγοράς με μετρητά ύψους 52,50 δολαρίων ανά μετοχή. Η συμφωνία αυτή ενισχύει τη θέση της εταιρείας στον τομέα των αυτοάνοσων νοσημάτων, καθώς αποκτά πρόσβαση στο πειραματικό φάρμακο nipocalimab, το οποίο στοχεύει παθήσεις που σχετίζονται με την παρουσία αυτοαντισωμάτων. Παράλληλα, η εξαγορά επεκτείνει την παρουσία της J&J στο κέντρο καινοτομίας του Cambridge, Massachussets. Παράλληλα, η Ευρωπαϊκή Επιτροπή ανακοίνωσε την ολοκλήρωση προκαταρκτικών συνομιλιών με την Johnson & Johnson για την προμήθεια πιθανού εμβολίου για την αντιμετώπιση του COVID-19. Η συμφωνία αυτή προβλέπει την δυνατότητα αγοράς ή δωρεάς 200 εκατομμυρίων δόσεων από τα κράτη μέλη της ΕΕ με προοπτική για επιπλέον 200 εκατομμύρια. Η Κομισιόν συνεχίζει τις διαπραγματεύσεις και με άλλες φαρμακευτικές εταιρίας στο πλαίσιο της ευρωπαϊκής στρατηγικής για την αντιμετώπιση της πανδημίας. Αντίστοιχα, στις Ηνωμένες Πολιτείες, η κυβέρνηση έχει δεσμεύσει συνολικά τουλάχιστον $ 9,4 δισεκατομμύρια για την ανάπτυξη και προμήθεια εμβολίων, με την Johnson & Johnson να λαμβάνει χρηματοδότηση 1 δισεκατομμυρίου για την παραγωγή 100 εκατομμυρίων δόσεων. Η συμφωνία περιλαμβάνει και δυνατότητα επέκτασης για επιπλέον 200 εκατομμύρια δόσεις. Συνολικά, έχουν συναφθεί συμφωνίες με πέντε εταιρείες για περισσότερες από 700 εκατομμύρια δόσεις, υπό την προϋπόθεση της αποτελεσματικότητάς τους.

Question:
What trends can be observed in the company’s revenue amount over the past few years? Please quote the piece(s) of news aligned with the finding(s), if any.

Answer:

Question: What trends can be observed in the company’s revenue amount over the past few years? Please quote the piece(s) of news aligned with the finding(s), if any.

Johnson & Johnson’s revenue showed a decline in the first half of 2020 due to the COVID-19 pandemic. For the first six months, total revenue was $39.0 B, down from $40.6B.

News Evidence:
 “...el conglomerado... facturó US$39.027 millones, un 3,8% menos que en el mismo intervalo del año pasado...”

Question: How does the company’s balance sheet reflect its financial health in terms of total amount of current assets and the ratio of total liability divided by total equity? Please provide only the final result(s); do not include any calculation steps. Please quote the piece(s) of news aligned with the finding(s), if any.

Johnson & Johnson reported $45.9B in total current assets. The ratio of total liabilities to equity was 1.51.

News Evidence:
None

Question: Are there any significant changes or irregularities in the amount of operating, investing and financing cash flow? Please quote the piece(s) of news aligned with the finding(s), if any.

Johnson & Johnson experienced significant changes in operating investing, and financing cash flows. operating cash flow decreased significantly from $9.5B to $6.8B, due to changes in accounts payable and accrued liabilities. Investing cash outflows increased significantly from $3.2B to $8.1B, due to investment purchase increase. Financing cash flow shifted from $10.1B. to to $4.7B, reflecting higher dividend payments and share repurchases.

News Evidence:
None

Question: What is the company's R&D ratio (R&D divided by revenue)? Please provide only the final result(s); do not include any calculation steps. Please quote the piece(s) of news aligned with the finding(s), if any.

The company’s R&D ratio for the six months ended June 28, 2020, is approximately 0.14.

News Evidence:
None